MediWound
MediWound
MDWD
NASDAQ
18.39
USD
6.92%
About
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 70.9K |
| Three Month Average Volume | 3.7M |
| High Low | |
| Fifty-Two Week High | 24 USD |
| Fifty-Two Week Low | 7.1 USD |
| Fifty-Two Week High Date | 05 Jul 2024 |
| Fifty-Two Week Low Date | 08 Sep 2023 |
| Price and Volume | |
| Current Price | 18.39 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -0.42% |
| Thirteen Week Relative Price Change | 5.35% |
| Twenty-Six Week Relative Price Change | 17.78% |
| Fifty-Two Week Relative Price Change | 77.25% |
| Year-to-Date Relative Price Change | 52.70% |
| Price Change | |
| One Day Price Change | 0.88% |
| Thirteen Week Price Change | 12.75% |
| Twenty-Six Week Price Change | 29.51% |
| Five Day Price Change | -0.86% |
| Fifty-Two Week Price Change | 122.10% |
| Year-to-Date Price Change | 80.83% |
| Month-to-Date Price Change | -4.37% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.42614 USD |
| Book Value Per Share (Most Recent Quarter) | 1.92424 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.40824 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.91003 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.4856 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.0732 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.17976 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.74513 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.16012 USD |
| Normalized (Last Fiscal Year) | -0.76035 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.74513 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.16012 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.74513 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.16012 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.52278 USD |
| Cash Per Share (Most Recent Quarter) | 3.14605 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.60057 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.00898 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.40974 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -32 |
| Cash Flow Revenue (Trailing Twelve Months) | -111 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -98.22% |
| Pretax Margin (Last Fiscal Year) | -34.95% |
| Pretax Margin (5 Year) | -38.19% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 19.15% |
| Gross Margin (Trailing Twelve Months) | 13.25% |
| Gross Margin (5 Year) | 43.27% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -81.83% |
| Operating Margin (Trailing Twelve Months) | -75.16% |
| Operating Margin (5 Year) | -32.00% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -35.94% |
| Net Profit Margin (Trailing Twelve Months) | -99.17% |
| Net Profit Margin (5 Year) | -38.43% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 8.20% |
| Tangible Book Value (5 Year) | 29.96% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 6.08% |
| Revenue Growth (3 Year) | 40.60% |
| Revenue Change (Trailing Twelve Months) | -22.51% |
| Revenue Per Share Growth | 18.75% |
| Revenue Growth (5 Year) | -4.95% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 64.66% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -783.77% |
| EPS Change (Trailing Twelve Months) | 10.00% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 11 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -22,860,000 |
| Net Debt (Last Fiscal Year) | -34,997,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11 |
| Price to Sales (Trailing Twelve Months) | 10 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 41 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 8 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 10 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 20 |
| Long Term Debt to Equity (Most Recent Quarter) | 36 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 4 |
| Quick Ratio (Most Recent Quarter) | 2 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -16,929,000 |
| Free Cash Flow (Trailing Twelve Months) | -22,266,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -3 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 21 |
| Total Debt to Equity (Most Recent Quarter) | 36 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -11.53% |
| Return on Assets (Trailing Twelve Months) | -32.83% |
| Return on Assets (5 Year) | -24.48% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -31.60% |
| Return on Equity (Trailing Twelve Months) | -75.66% |
| Return on Equity (5 Year) | -95.96% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -14.35% |
| Return on Investment (Trailing Twelve Months) | -49.28% |
| Return on Investment (5 Year) | -32.92% |